Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    cholangiocarcinoma AND cisplatin 0.5 mg/ml | Open Studies
Show Display Options
Rank Status Study
1 Unknown  PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)
Condition: Cholangiocarcinomas
Interventions: Drug: Cisplatin, Gemcitabine, Panitumumab;   Drug: Cisplatin, Gemcitabine

Indicates status has not been verified in more than two years